Literature DB >> 13680354

VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis.

Marc Tjwa1, Aernout Luttun, Monica Autiero, Peter Carmeliet.   

Abstract

Blood vessels are crucial for normal development and growth by providing oxygen and nutrients. As shown by genetic targeting studies in mice, zebrafish and Xenopus blood vessel formation (or angiogenesis) is a multistep process, which is highly dependent on angiogenic growth factors such as VEGF, the founding member of the VEGF family. VEGF binds to the tyrosine kinase receptors VEGFR-1 and VEGFR-2, and loss of VEGF or its receptors results in abnormal angiogenesis and lethality during development. In contrast, PlGF, another member of this family, binds only to VEGFR-1, and appears to be crucial exclusively for pathological angiogenesis in the adult. However, the expression of VEGFR-1 and VEGFR-2 on non-vascular cells suggests additional biological properties for these growth factors. Indeed, the VEGF family and its receptors determine development and homeostasis of many organs, including the respiratory, skeletal, hematopoietic, nervous, renal and reproductive system, independent of their vascular role. These new insights broaden the activity spectrum of these "angiogenic" growth factors, and may have therapeutic implications when using these growth factors for vascular and/or non-vascular purposes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680354     DOI: 10.1007/s00441-003-0776-3

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  38 in total

1.  Systemic Inflammation during the First Postnatal Month and the Risk of Attention Deficit Hyperactivity Disorder Characteristics among 10 year-old Children Born Extremely Preterm.

Authors:  Elizabeth N Allred; Olaf Dammann; Raina N Fichorova; Stephen R Hooper; Scott J Hunter; Robert M Joseph; Karl Kuban; Alan Leviton; Thomas Michael O'Shea; Megan N Scott
Journal:  J Neuroimmune Pharmacol       Date:  2017-04-12       Impact factor: 4.147

Review 2.  Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation.

Authors:  Holger Scholz; Kay-Dietrich Wagner; Nicole Wagner
Journal:  Pflugers Arch       Date:  2008-12-04       Impact factor: 3.657

3.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

4.  Controlled Angiogenesis in Peptide Nanofiber Composite Hydrogels.

Authors:  Navindee C Wickremasinghe; Vivek A Kumar; Siyu Shi; Jeffrey D Hartgerink
Journal:  ACS Biomater Sci Eng       Date:  2015-08-20

5.  Biochemical markers for prediction of preclampsia: review of the literature.

Authors:  Santo Monte
Journal:  J Prenat Med       Date:  2011-07

Review 6.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

7.  A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1.

Authors:  Rosana D Meyer; Moosa Mohammadi; Nader Rahimi
Journal:  J Biol Chem       Date:  2005-11-14       Impact factor: 5.157

8.  CD133 identifies a human bone marrow stem/progenitor cell sub-population with a repertoire of secreted factors that protect against stroke.

Authors:  Benjamin Bakondi; Issei S Shimada; Anthony Perry; James R Munoz; Joni Ylostalo; Alan B Howard; Carl A Gregory; Jeffrey L Spees
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

Review 9.  Potential markers of preeclampsia--a review.

Authors:  Simon Grill; Corinne Rusterholz; Rosanna Zanetti-Dällenbach; Sevgi Tercanli; Wolfgang Holzgreve; Sinuhe Hahn; Olav Lapaire
Journal:  Reprod Biol Endocrinol       Date:  2009-07-14       Impact factor: 5.211

10.  Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases.

Authors:  Siba P Raychaudhuri; Smriti K Raychaudhuri
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.